Moreover, BJIKT did not affect the PD-1/PD-L1 binding affinity (Figure 2G), suggesting that BJIKT exerts antitumor effects by regulating the immune response in the tumor microenvironment, rather than exerting direct cytotoxic effects on CRC cells. The gene discussed is PDCD1; the disease is colorectal carcinoma.